...
首页> 外文期刊>Biochemical Genetics >Polyprenol-Based Lipofecting Agents for In Vivo Delivery of Therapeutic DNA to Treat Hypertensive Rats
【24h】

Polyprenol-Based Lipofecting Agents for In Vivo Delivery of Therapeutic DNA to Treat Hypertensive Rats

机译:基于聚丙烯酚的脂脂素用于治疗治疗高血压大鼠的治疗性DNA

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Development of efficient vectors for transfection is one of the major challenges in genetic engineering. Previous research demonstrated that cationic derivatives of polyisoprenoids (PTAI) may serve as carriers of nucleic acids. In the present study, the effectiveness of two PTAI-based formulations (PTAI-6-8 and 10-14) was investigated and compared to the commercial reagents. The purpose of applied gene therapy was to enhance the expression of vascular endothelial growth factor (VEGF-A) in the renal medulla of spontaneously hypertensive rats (SHR) and to test its potential as a novel antihypertensive intervention. In the first part of the study (in vitro), we confirmed that PTAI-based lipoplexes efficiently transfect XC rat sarcoma cells and are stable in 37 degrees C for 7 days. In the in vivo experiments, we administered selected lipoplexes directly to the kidneys of conscious SHR (via osmotic pumps). There were no blood pressure changes and VEGF-A level in renal medulla was significantly higher only for PTAI-10-14-based formulation. In conclusion, despite the promising results, we were not able to achieve VEGF-A expression level high enough to verify VEGF-A gene therapy usefulness in SHR. However, results of our study give important indications for the future development of PTAI-based DNA carriers and kidney-targeted gene delivery.
机译:用于转染的有效载体的开发是基因工程中的主要挑战之一。以前的研究表明,多异戊二烯(PTAI)的阳离子衍生物可以用作核酸的载体。在本研究中,研究了两种基于PTAI的制剂(PTAI-6-8和10-14)的有效性并与商业试剂进行了比较。应用基因疗法的目的是增强自发性高血压大鼠(SHR)肾髓质中血管内皮生长因子(VEGF-A)的表达,并将其作为新型抗高血压干预的潜力测试。在该研究的第一部分(体外)中,我们证实了基于PTAI的脂质体有效地转染XC大鼠肉瘤细胞,并在37℃下稳定7天。在体内实验中,我们将选定的脂肪物直接施用于意识的肾脏(通过渗透泵)。对于基于PTAI-10-14的制剂,肾髓内的VEGF-A水平显着高得多。总之,尽管结果有希望的结果,但我们无法实现VEGF-A表达水平足够高,以验证VEGF-A基因治疗SHR中的有用性。然而,我们的研究结果为PTAI的DNA载体和肾靶向基因递送的未来发展提供了重要的迹象。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号